Released Presentations
PLENARY SESSIONS

FIRST PLENARY SESSION: TAKING STOCK OF THE LEARNING HEALTH CARE SYSTEM: WHAT HAVE WE ACHIEVED AND WHY DOES IT MATTER?

Presentation
Penny Mohr, Senior Program Officer, Improving Healthcare Systems, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA
Presentation
Lewis G. Sandy, Senior Vice President, Clinical Advancement, UnitedHealth Group, Minneapolis, MN, USA
Presentation
Sarah Greene, Associate Director, CER Methods and Infrastructure, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA

 

SECOND PLENARY SESSION: COST-EFFECTIVENESS AND CLINICAL PRACTICE GUIDELINES: HAVE WE REACHED A TIPPING POINT?

Presentation
Lou Garrison, Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA
Presentation
Michael Drummond, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Presentation
Mark A. Hlatky, Professor of Health Research and Policy and Professor of Medicine (Cardiovascular Medicine), Stanford University School of Medicine, Stanford, CA, USA
Presentation
Peter P. Yu, Director of Cancer Research, Palo Alto Medical Foundation, Sunnyvale, CA and President, American Society of Clinical Oncology (ASCO), Alexandria, VA, USA

 

THIRD PLENARY SESSION: BIG DATA, BIG SYSTEMS, AND BETTER EVIDENCE: WHAT PROGRESS?

Presentation
Adrian Towse, Director, Office of Health Economics, London, UK
Presentation
Ari Caroline, Chief Analytics Officer, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Presentation
Paul Wallace, Chief Medical Officer & Senior Vice President, Clinical Translation, Optum Labs and Chair, Board of Directors, AcademyHealth, Cambridge, MA, USA

 

ISSUE PANEL PRESENTATIONS

IP1 : SHOULD THE NAME OF THE GAME BE MORE “SKIN IN THE GAME”? THE SCOPE & CONSEQUENCES OF RX COST SHIFTING FROM PAYERS TO PATIENTS (Invited Issue Panel)

Presentation
Elizabeth Hargrave, Principal Research Scientist, NORC, Bethesda, MD, USA
Presentation
Elise Gould, Senior Economist & Director of Health Policy Research, Economic Policy Institute, Washington, DC, USA

 

IP3 : CHALLENGES AND OPPORTUNITIES FOR PRAGMATIC CLINICAL TRIALS – SHOULD EUROPE AND THE UNITED STATES APPROACH THEM DIFFERENTLY?

Presentation
Tjeerd Van Staa, Professor, Farr Institute, University of Manchester, Manchester, UK
Presentation
Bryan R Luce, Chief Science Officer, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA
Presentation
Rafael Alfonso-Cristancho, Director, Value Evidence Analytics, Research and Development, GlaxoSmithKline (GSK), King of Prussia, PA, USA

 

IP4 : WHAT IS THE VALUE OF BIG DATA IN COMPARATIVE EFFECTIVENESS RESEARCH AND CLINICAL DECISION MAKING?

Presentation
William H. Crown, Chief Scientific Officer, Optum Labs, Cambridge, MA, USA
Presentation
Sarah Greene, Associate Director, CER Methods and Infrastructure Program, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA
Presentation
Miguel Hernan, Professor of Epidemiology and Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, USA
Presentation
Milton C Weinstein, Henry J. Kaiser Professor of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, MA, USA

 

IP5 : PROS AND BEYOND: ARE THEY FIT FOR PURPOSE TO IMPROVE HEALTH CARE POLICY AND PRACTICE?

Presentation
Kristi Mitchell, Senior Vice President, Avalere Health, Washington, DC, USA
Sachin Kamal-Bahl, Vice President & Head, Global Health & Value Innovation Center, Pfizer, Philadelphia, PA, USA

 

IP6 : HOW SHOULD THE FDA REGULATE THE COMMUNICATION OF HEALTH ECONOMIC DATA BY PHARMACEUTICAL COMPANIES TO PAYERS?

Presentation
Peter J. Neumann, Professor & Director, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies,Tufts Medical Center, Boston, MA, USA
Joseph Jackson, Principal, Health Outcomes Insights LLC, Lavallette, NJ, USA
Laurie Burke, Founder, LORA Group, Royal Oak, MD, USA
Albert F. Cacozza, Partner, Ropes & Gray, Washington, DC, USA

 

IP8 : ARE WE COMFORTABLE APPLYING EXISTING QUALITY-DRIVEN ADHERENCE MEASUREMENT METHODOLOGIES TO SPECIALTY PHARMACEUTICAL PRODUCTS AND WHAT ARE THE RISKS, ESPECIALLY IF USING ADMINISTRATIVE CLAIMS DATABASES?

Presentation
Craig Schilling, Chair, Pharmacy Quality Alliance (PQA) Adherence Committee and Vice President, Patient Programs, Optum, Eden Prairie, MN, USA
Stephen M Lund, Executive Vice President, Strategic Initiatives, Senderra Rx Specialty Pharmacy, Richardson, TX, USA
Presentation
Michael Ingham, Director, HECOR, Janssen Scientific Affairs, LLC, Horsham, PA, USA

 

IP9 : CONTINUOUS PATIENT ENGAGEMENT: HOW DO WE PARTNER WITH PATIENTS THROUGHOUT THE RESEARCH LIFE CYCLE?

Presentation
Marvin Mack, Chief Executive Officer, Center for Mind & Esteem Development, Baltimore, MD, USA
C. Daniel Mullins, Professor & Chair, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA
Emil Chiauzzi, Research Director, PatientsLikeMe, Cambridge, MA, USA
Daniel Frye, Executive Director, NJ Commission for the Blind and Visually Impaired, Newark, NJ, USA

 

IP10 : EARLY ACCESS TO MEDICINES: WHAT IS IN IT FOR PAYERS?

Presentation
Mark Trusheim, Visiting Scientist & Executive in Residence, Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA, USA
Presentation
Adrian Towse, Director, Office of Health Economics (OHE), London, UK
Presentation
Dan Ollendorf, Chief Review Officer, Institute for Clinical and Economic Review, Boston, MA, USA

 

IP11 : THE $2.6 BILLION QUESTION: WHY ARE DRUG DEVELOPMENT COSTS RISING AND CAN WE AFFORD IT? (Invited Issue Panel)

Presentation
Adrian Towse, Director, Office of Health Economics (OHE), London, UK
Presentation
Lou Garrison, Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA

 

IP12 : PATIENT-FOCUSED DRUG DEVELOPMENT: ARE POLICY MAKERS LISTENING?

Presentation
John F P Bridges, Associate Professor, Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Frank W Rockhold, Senior Vice President, Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Cary, NC, USA
Holly Peay, Senior Vice President, Community Research, Parent Project Muscular Dystrophy, Hackensack, NJ, USA
Mark Walderhaug, Associate Director for Risk Assessment, Center for Biologics Evaluation & Research, Office of Biostatistics & Epidemiology, U.S. Food & Drug Administration, Silver Spring, MD, USA

 

IP13 : CAN THE EUNETHTA HTA CORE MODEL© HELP TO ENSURE AN ALIGNED CONCEPT OF VALUE BETWEEN HTA, DECISION MAKERS/PAYERS, AND PHARMA INDUSTRY?

Presentation
David Shum, Head, Market Access, F. Hoffmann La Roche, Mississauga, ON, Canada
Presentation
Chander Sehgal, Director, Common Drug Review (CDR) & Optimal Use of Drugs, Canadian Agency for Drugs and Technologies in Health (CADTH), Toronto, ON, Canada
Presentation
Finn Boerlum Kristensen, Secretariat Director, Danish Health and Medicines Authority, Copenhagen, Denmark

 

IP14 : DISTINGUISHING BIOSIMILARITY – HOW CAN WE GENERATE REAL-WORLD EVIDENCE TO SUPPORT DECISION-MAKING?

Presentation
Robert W Dubois, Chief Science Officer, National Pharmaceutical Council, Washington, DC, USA
Presentation
Nancy A. Dreyer, Senior Vice President, Global Chief of Scientific Affairs, Real-World & Late Phase Research, Quintiles, Cambridge, MA, USA
Presentation
Jaclyn L Bosco, Director of Epidemiology, Real-World & Late Phase Research, Quintiles, Cambridge, MA, USA
Presentation
Jeff White, Director, Drug Evaluation and Clinical Analytics, Clinical Pharmacy Policy, Anthem, Inc., Costa Mesa, CA, USA

 

IP15 : THE CONTROVERSIAL ROLE OF COST-EFFECTIVENESS ANALYSES (CEA) AND INCREMENTAL COST-EFFECTIVENESS RATIO (ICER) THRESHOLDS IN VALUE-BASED ASSESSMENTS (VBA) OF HEALTH TECHNOLOGIES: WHAT ARE THE FUTURE CHALLENGES?

Presentation
Zeba M. Khan, Vice President, Celgene Corporation, Summit, NJ, USA
Presentation
Ron Akehurst, Professor Emeritus of Health Economics, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
Presentation
Michael Schlander, Chairman & Scientific Director, Institute for Innovation & Valuation in Health Care, University of Heidelberg, Wiesbaden, Germany
Presentation
John Proach, Executive Vice President, Pricing and Market Access, Market Access Solutions LLC, Raritan, NJ, USA

 

IP16 : DO STATE MEDICAID FORMULARIES WORSEN OUTCOMES FOR PATIENTS WITH MENTAL ILLNESS?

Presentation
Darius N. Lakdawalla, Quintiles Chair in Pharmaceutical Development and Regulatory Innovation, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
Anupam B. Jena, Assistant Professor of Health Care Policy and Medicine, Harvard Medical School, Boston, MA, USA
Dana P. Goldman, Leonard D. Schaeffer Chair & Director, Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, CA, USA
Seth A. Seabury, Associate Professor of Research, Department of Emergency Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA

 

IP17 : VALUE-BASED FORMULARY DESIGN (VBFD): IS PREMERA A VOICE CRYING IN THE WILDERNESS?

Presentation
Kathleen E. Hughes, Vice President, Health Economics and Outcomes Research, Avalere Health LLC, Washington, DC, USA
Presentation
Dan Danielson, Pharmacy Manager, Clinical Services, Premera Blue Cross, Mountlake Terrace, WA, USA

 

IP18 : COMPETITIVE BIDDING FOR THERAPEUTICALLY-EQUIVALENT BRANDED PHARMACEUTICALS: PROMISE OR THREAT?

Presentation
Josephine A. Mauskopf, Vice President, Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA
Susan Hogue, Senior Director, Value Insight and Access Strategy, Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA
David W. Miller, Senior Vice President, Global Market Access, Biogen Idec, Maidenhead, UK

 

IP19 : READY FOR RISK SHARING? CHALLENGES AND IMPLICATIONS FOR MANUFACTURERS

Presentation
Sherry Thornton, Vice President, Healthcare Alliances, Medtronic, Inc., Memphis, TN, USA
Kim White, Senior Consultant, Numerof & Associates, St. Louis, MO, USA
Bryan Gilpin, Director, Customer Solutions & International Operations, Boston Scientific Corporation, Marlborough, MA, USA
Don Liss, Vice President, Clinical Programs and Policy, Independence Blue Cross, Philadelphia, PA, USA

 

IP20 : APPLICATION OF PROMIS TOOLS IN PHARMACEUTICAL AND DEVICE INDUSTRY STUDIES: ARE WE MOVING THE WHEEL FORWARD?

Presentation
Ashley Slagle, Clinical Outcome Assessment Qualification Scientific Coordinator & Study Endpoints Reviewer, U.S. Food and Drug Administration, Silver Spring, MD, USA
Presentation
Stacie Hudgens, Managing Partner, Clinical Outcomes Solutions, Tucson, AZ, USA
Presentation
David Cella, Professor, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

 

WORKSHOP PRESENTATIONS

W1 : PATIENT-CENTERED BENEFIT-RISK ANALYSIS: REGULATORY DEVELOPMENTS AND PROSPECTS

Presentation
Lou Garrison, Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA
F. Reed Johnson, Senior Research Scholar, Duke Clinical Research Institute, Duke University, Durham, NC, USA
John F.P. Bridges, Associate Professor, Department of Health Policy and Management and International Health, John Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Bennett Levitan, Senior Director, Benefit-risk Assessment, Epidemiology, Janssen Research & Development, LLC, Titusville, NJ, USA

 

W3 : SELECTION BIAS AND COST ALLOCATION IN PATIENTS WITH POLYCHRONIC DISEASE

Presentation
Lei Liu, Associate Professor, Preventive Medicine-Biostatistics, Northwestern University, Chicago, MA, USA
Robin Turpin, Director, Takeda Pharmaceuticals USA, Deerfield, IL, USA
Kathy L. Schulman, Managing Director, Outcomes Research Solutions, Inc., Bolton, MA, USA

 

W4 : IDENTIFYING PATIENTS WITH RARE DISORDERS USING ADMINISTRATIVE DATA

Presentation
Daniel C. Malone, Professor of Pharmacy, College of Pharmacy and Associate Professor, Mel & Enid Zuckerman College, University of Arizona, Tucson, AZ, USA
Presentation
Eric J. Bell, Principal, One Tall Tree, LLC, Seattle, WA, USA
Presentation
Wei-Shi Yeh, Associate Director, Global Market Access, Biogen Idec, Cambridge, MA, USA
Presentation
Edward P. Armstrong, President, Strategic Therapeutics, LLC, Oro Valley, AZ, USA

 

W5 : INDIRECT COMPARISONS FOR SINGLE-ARM TRIALS OR TRIALS WITHOUT COMMON COMPARATOR ARMS: WHAT METHODS ARE AVAILABLE, HOW HAVE THEY BEEN USED AND HOW CAN WE EVALUATE RESULTS?

Presentation
Anupama Kalsekar, Director, World Wide Health Economics and Outcomes Research, Bristol-Myers Squibb, Princeton, NJ, USA
Yong Yuan, Director, World Wide Health Economics and Outcomes Research, Bristol-Myers Squibb Pharmaceuticals Ltd, Princeton, NJ, USA
James Signorovitch, Vice President, Health Economics and Outcomes Research, Analysis Group, Inc., Boston, MA, USA
Elyse Swallow, Manager, Health Economics and Outcomes Research, Analysis Group, Inc., Boston, MA, USA

 

W6 : APPLYING DYNAMIC SIMULATION MODELING METHODS IN HEALTH CARE DELIVERY RESEARCH – THE SIMULATE CHECKLIST AND EMERGING GOOD PRACTICES: REPORTS OF THE ISPOR SIMULATION MODELING EMERGING GOOD PRACTICES TASK FORCE

Presentation
Deborah A. Marshall, Canada Research Chair, Health Services and Systems Research & Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Alberta Bone and Joint Health Institute, Calgary, AB, Canada
Kalyan S. Pasupathy, Faculty, Healthcare Policy & Research, Mayo Clinic, Rochester, MN, USA
Peter Wong, Vice President & Chief Performance Improvement Officer, Illinois Divisions and Medical Group, HSHS, Belleville, IL, USA
Mitchell Higashi, Chief Economist, GE Healthcare, Barrington, IL, USA

 

W7 : ASSESSING PERFORMANCE OUTCOME MEASURES FOR REGULATORY REVIEW: CONCEPTUAL AND METHODOLOGICAL CHALLENGES WITH REAL WORLD EXAMPLES

Presentation
Ashley Slagle, Clinical Outcome Assessment Qualification Scientific Coordinator & Study Endpoints Reviewer, U.S. Food and Drug Administration, Silver Spring, MD, USA
Presentation
Rachel Simone Ballinger, Senior Outcomes Researcher, Patient-Reported Outcomes, ICON, Oxford, UK
Presentation
Elizabeth Nicki Bush, Research Scientist, Global Patient Outcomes and Real World Evidence, Eli Lilly, Indianapolis, IN, USA
Presentation
Diana Rofail, Global Head of Patient-Centered Outcomes Research, Neuroscience and Metabolism, Roche Products Limited, Welwyn Garden City, UK

 

W8 : DESIGN OF BUNDLED PAYMENT IN THE AMBULATORY SETTING OF CARE

Presentation
Joshua T. Cohen, Associate Professor, Center for the Evaluation of Value and Risk in Health,Tufts Medical Center, Boston, MA, USA
Presentation
Mike Ciarametaro, Director of Research, National Pharmaceutical Council, Washington, DC, USA
Presentation
Lili Brillstein, Director, Episodes of Care, Horizon Healthcare Innovations, Newark, NJ, USA
Presentation
Michael del Aguila, Vice President, HEOR US Medical, Bristol-Myers Squibb, New York, NY, USA

 

W9 : METHODOLOGICAL CHOICES FOR ANALYZING CLUSTER-CORRELATED DATA IN LARGE PATIENT DATABASES

Presentation
Samuel Aballéa, Vice President, HEOR, Creativ-Ceutical, Paris, France
Katia Thokagevistk, Manager, HEOR, Creativ-Ceutical, Paris, France
Steve Sherman, Director, HEOR, Creativ-Ceutical, Chicago, IL, USA
Firas Dabbous, Research Analyst, Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, IL, USA

 

W10 : RARE DISEASES IN THE ERA OF BIG DATA: SELECTION BIAS IN SMALL SAMPLES

Presentation
Cori Blauer-Peterson, Senior Research Analyst, Health Economics and Outcomes Research, Optum, Eden Prairie, MN, USA
Jonathan C. Johnson, Associate Director, HEOR, Optum, Eden Prairie, MN, USA
Zhimei Liu, Director, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Nicole M. Engel-Nitz, Senior Researcher, HEOR, Optum, Eden Prairie, MN, USA

 

W11 : CAN WE MAKE COMPARATIVE EFFECTIVENESS USEFUL FOR CLINICIANS AND PATIENTS OR IS IT JUST FOR HEALTH TECHNOLOGY ASSESSMENTS?

Presentation
Christopher O'Regan, Head of Health Technology Assessment & Outcomes, Merck Sharp & Dohme Limited, Hertfordshire, UK
Presentation
Edward J Mills, Visiting Associate Professor, Stanford University, Stanford, CA, USA
Presentation
Sonal Singh, Professor, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA

 

W13 : PATIENT- AND OBSERVER-REPORTED OUTCOMES (PROS & OBSROS) MEASUREMENT IN RARE DISEASE CLINICAL TRIALS — EMERGING GOOD PRACTICES

Presentation
Donald L. Patrick, Professor, Seattle Quality of Life Group and Biobehavioral Cancer Training Program, University of Washington, Seattle, WA, USA
Katy Benjamin, Director, Patient Reported Outcomes, ICON, Bethesda, MD, USA
Eleanor Perfetto, Associate Professor, Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, MD, USA
Laurie Burke, Founder, LORA Group, Royal Oak, MD, USA

 

W14 : CHARTING A PATH FOR THE ELICITATION OF PREFERENCES: PERSPECTIVES ON THE EFFECTIVE USE OF PREFERENCE-ELICITATION METHODS

Presentation
Josephine A. Mauskopf, Vice President, Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA
Juan Marcos Gonzalez, Senior Research Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA
Maarten J. IJzerman, Professor & Chair, Department of Health Technology & Services Research, University of Twente and MIRA Institute for Biomedical Technology & Technical Medicine, Enschede, The Netherlands

 

W15 : THE ISPOR MCDA TASK FORCE: HOW BEST TO USE IT IN HEALTH CARE DECISION MAKING

Presentation
Kevin Marsh, Senior Director, Modelling and Simulation, Evidera, London, UK
Praveen Thokala, Research Fellow, School of Health and Related Research, University of Sheffield, Sheffield, UK
Nancy Devlin, Director of Rearch, Office of Health Economics, London, UK
Maarten J. IJzerman, Professor & Chair, Department of Health Technology & Services Research, University of Twente and MIRA Institute for Biomedical Technology & Technical Medicine, Enschede, The Netherlands

 

W16 : MAXIMIZING THE UTILITY OF REAL WORLD EVIDENCE: INTEGRATION OF STRUCTURED EMR DATA, UNSTRUCTURED EMR DATA, AND BILLING DATA FOR ECONOMICS AND OUTCOMES RESEARCH IN ONCOLOGY

Presentation
Kim Saverno, Director of Pharmacoeconomics, Vector Oncology, Memphis, TN, USA
Mark S Walker, Vice President of Scientific Affairs, Vector Oncology, Memphis, TN, USA
Kathy L. Schulman, Managing Director, Outcomes Research Solutions, Inc., Bolton, MA, USA
Arliene Ravelo, Associate Director, US Medical Affairs, Genentech, Inc., South San Francisco, TN, USA

 

W17 : INFORMATICS AND INTEROPERABILITY: SPEAKING THE SAME LANGUAGE

Presentation
Daniel C. Malone, Professor of Pharmacy, College of Pharmacy and Associate Professor, Mel & Enid Zuckerman College, University of Arizona, Tucson, AZ, USA
Presentation
Richard Boyce, Assistant Professor, Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA
Presentation
Scott D Nelson, Post­doctoral Fellow, Medical Informatics, Department of Veterans Affairs, Salt Lake City, UT, USA
Presentation
Olivier Bodenreider, Branch Chief, Cognitive Science Branch, U.S. National Library of Medicine, Bethesda, MD, USA

 

W19 : MODELING IN ONCOLOGY: THE TAMING OF THE SHREWS?

Presentation
Sorrel Wolowacz, Head, European Health Economics, RTI Health Solutions, Manchester, UK
Noemi Muszbek, Senior Research Scientist, Evidera, London, UK
Agnes Benedict, Executive Director, Evidera, Budapest, Hungary

 

W20 : INCORPORATING SOCIAL VALUES INTO COST-EFFECTIVENESS ANALYSIS

Presentation
Christopher McCabe, Professor, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
Mike Paulden, Senior Research Associate, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
James F. O'Mahony, Post-Doctoral Researcher, Department of Health Policy & Management, Trinity College Dublin, Dublin, Ireland

 

W22 : HOW TO DESIGN AN ANALYTIC STRATEGY FOR EVIDENCE GENERATION FOR DECISION MAKERS

Presentation
Lou Garrison, Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA
Presentation
Omar Dabbous, Head of Value Evidence Analytics, GlaxoSmithKline, King of Prussia, PA, USA
Presentation
Rafael Alfonso-Cristancho, Director, Value Evidence Analytics, Research and Development, GlaxoSmithKline (GSK), King of Prussia, PA, USA

 

W23 : INTEGRATED LONGITUDINAL DATA: HOW DYNAMIC DATA COLLECTION CAN BIAS ESTIMATORS AND POSSIBLE SOLUTIONS

Presentation
William H Olson, Leader, Research and Analysis Strategy, Janssen Scientific Affairs, LLC, Titusville, NJ, USA
Henry J. Henk, Vice President & Principal Consultant, Optum, Eden Prarie, MN, USA

 

W24 : A PRACTICAL APPROACH TO UNDERSTAND THE CONCEPTS AND METHODS USED TO ASSESS HETEROGENEITY AND INCONSISTENCY IN NETWORK META-ANALYSES

Presentation
Sonya J Snedecor, Executive Director, Health Economics, Pharmerit International, Bethesda, MD, USA
Dipen Patel, Director, HEOR, Pharmerit International, Bethesda, MD, USA
Berhanu Alemayehu, Director, Outcomes Research, CORE, Primary Care Merck, Gaithersburg, MD, USA
Varun Ektare, Senior Analyst, Pharmerit International, Bethesda, MD, USA

 

W26 : BACK TO THE FUTURE: LEARNING THE LESSONS IN VALUING EQ-5D-3L HEALTH STATES

Presentation
Roisin Adams, Deputy Head, National Centre for Pharmacoeconomics, Dublin, Ireland
Paul Kind, Professor, Academic Unit of Health Economics, University of Leeds, Leeds, UK
Mônica Viegas, Professor, Economics Department, Center for Regional Development and Planning, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

 

W27 : WHEN BETTER THINGS HAPPEN TO A GOOD MODEL: A DEVELOPMENT OF THE DIFFERENCE IN DIFFERENCES (DD) MODEL INTO A DIFFERENCE IN DIFFERENCES IN DIFFERENCES IN DIFFERENCES (DDDD) MODEL WHEN ANALYZING THE EFFECT OF AN INTERVENTION

Presentation
Yanru Qiao, Data Analyst, Department of Clinical Pharmacy, The University of Tennessee College of Pharmacy, Memphis, TN, USA
Ya-Chen Tina Shih, Professor of Health Economics, & Section Chief, Section of Cancer Economics and Policy, Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Junling Wang, Associate Professor, Department of Clinical Pharmacy, The University of Tennessee College of Pharmacy, Memphis, TN, USA
Hemant Phatak, Group Director, Global Health Economics & Outcomes Research, Bristol-Myers Squibb Company, Princeton, NJ, USA

 

W28 : HORIZON SCANNING – IDENTIFYING AND ESTIMATING FUTURE IMPACT OF EMERGING INNOVATIONS ON U.S. HEALTH CARE

Presentation
Karen Schoelles, Project Director, AHRQ Healthcare Horizon Scanning System and Director, ECRI Institute Evidence-based Practice Center, Technology Assessment, ECRI Institute, Plymouth Meeting, PA, USA

 

W29 : STRATEGIES FOR ASSESSING THE PATIENT-LEVEL ECONOMIC IMPACT OF CANCER DIAGNOSIS

Presentation
Amy Davidoff, Senior Research Scientist, Cancer Prevention and Control, Yale School of Public Health, New Haven, CT, USA
Presentation
Veena Shankaran, Assistant Professor, Division of Medical Oncology, University of Washington, Seattle, WA, USA
Presentation
Donatus Ekwueme, Senior Health Economist, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Chamblee, GA, USA

 

W30 : WARRANTING BUDGET PREDICTABILITY THROUGH MANAGED ENTRY AGREEMENTS AND INSURANCE-BASED MECHANISMS

Presentation
Olivier Ethgen, Adjunct Professor, Health Economics, University of Liege, Liege, Belgium
Augustin Terlinden, Health Economist, BLUE ANTIDOTE, Tervuren, Belgium

 

W31 : DEVELOPMENTS AND COMMUNICATION SINCE THE ISSUANCE OF FDA’S GUIDANCE TO INDUSTRY ON PATIENT-REPORTED OUTCOMES: THEN AND NOW

Presentation
Paivi Miskala, Founder, ProCon Global, LLC, Rockville, MA, USA
Presentation
Somali Misra Burgess, CEO & Research Director, Strategic Outcomes Services, Mission Viejo, CA, USA
Presentation
Brooke Witherspoon, Associate Director, Research & Operations, Endpoint Outcomes, Boston, MA, USA

 

ISPOR FORUMS

F1 : MEASUREMENT OF HEALTH STATE UTILITY VALUES FOR ECONOMIC MODELS IN CLINICAL STUDIES – FINDINGS OF THE GOOD PRACTICES TASK FORCE

Presentation
Sorrel Wolowacz, Head, European Health Economics, RTI Health Solutions, Manchester, UK
Andrew Lloyd, Scientific Advisor, Patient Reported Outcomes, ICON plc., Oxford, UK
Andrew Briggs, William R. Lindsay Professor of Health Economics, Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK
Lynda Doward, European Head, Patient-Reported Outcomes, RTI Health Solutions, Manchester, UK

 

F2 : CLINICAL OUTCOME ASSESSMENTS (COAS): A CONCEPTUAL FOUNDATION AND DEVELOPING AND EVALUATING CLINICIAN-REPORTED OUTCOME (CLINRO) INSTRUMENTS TO ASSESS TREATMENT BENEFIT: EMERGING GOOD PRACTICES

Presentation
Stefan Cano, Co-Founder and Chief Science Officer, Modus Outcomes, Stotfold, UK
Patrick Marquis, President, Twolegs Consulting, Newton, MA, USA
John H. Powers, Associate Clinical Professor of Medicine, George Washington University School of Medicine, Washington, DC, USA
Laurie B. Burke, Founder, Lora Group, LLC, Royal Oak, MD, USA and Former Director, Study Endpoints and Labeling Development, ONDIO, CDER, U.S. Food & Drug Administration, Silver Spring, MD, USA
Donald Patrick, Professor, Department of Health Services & Director, Seattle Quality of Life Group & Biobehavioral Cancer Training Program, University of Washington, Seattle, WA, USA

 

F3 : PATIENT ENGAGEMENT IN HEALTH ECONOMIC AND OUTCOMES RESEARCH: CURRENT AND FUTURE ISPOR INITIATIVES

Presentation
Emil Chiauzzi, Research Director, PatientsLikeMe, Cambridge, MA, USA
Todd Berner, XX, XX, XX, Northbook, IL, USA
Don Husereau, Senior Associate, Institute of Health Economics & Adjunct Professor, Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada
Amie Scott, Business Health Research Analyst, SEAS Capital Partners, LLC, Plymouth, MI, USA
Rob Camp, Communications Manager, EUPATI, Barcelona, Spain

 

F4 : FROM COST-EFFECTIVENESS TO EQUITY: CHALLENGES FACING HEALTH CARE SYSTEMS IN LATIN AMERICA

Presentation
Marcelo Fonseca, Professor, Assistant Physician, Federal University of São Paulo, São Paulo, Brazil
Presentation
Manuel Antonio Espinoza, Chair-elect, ISPOR Latin America Consortium Executive Committee, Professor of Health Economics and Chief Unit of Health Technology Assessment, Faculty of Medicine, Santiago, Chile
Presentation
Rosa Maria Galindo Suarez, Deputy General Director of Prioritization, General Health Council, Mexico City, Mexico
Presentation
Diego Rosselli, Associate professor, Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogota, Colombia
Presentation
Hector Castro, Chief Executive Officer, Health Technology Assessment Institute of Colombia (IETS), Bogota, Colombia

 

F5 : INTEGRATING BIG DATA INTO REAL WORLD PRACTICE

Presentation
William H. Crown, Chief Scientific Officer, Optum Labs, Cambridge, MA, USA
Presentation
Marc Berger, Vice President, Real World Data and Analytic, Pfizer, Inc., New York, NY, USA

 

F6 : SYNCING INFORMATION CHAINS WITH HEALTH SYSTEMS DEVELOPMENT FOR BETTER OUTCOMES

Presentation
Gabriela Tannus, Owner & Health Economics Director, Axia.Bio Consulting, Sao Paolo, Brazil
Presentation
Vitaly V. Omelianovskiy, Director, Centre of HTA, Moscow, Russia
Presentation
Jitendar Sharma, Head, Division of Healthcare Technology, National Health Systems Resource Center, Ministry of Health & Family Welfare, New Delhi, India
Presentation
Kun Zhao, Professor & Director, Division of Health Technology Assessment, China National Health Development, Research Center, National Health and Family Planning Commission (NHFPC), Beijing, China
Presentation
Nikash Bagirathi, Managed Healthcare Manager, Medtronic, Johannesburg, South Africa

 

F7 : BUDGET IMPACT ANALYSIS OF EPIDEMIC DISEASES ACROSS AFRICA

Presentation
Peter Agyei-Baffour, President, ISPOR Ghana Chapter and Lecturer & Researcher, Department of Community Health, School of Medical Sciences, Kwame Nkrumah University of Sciences and Technology (KNUST), Kumasi, Ghana
Presentation
Anthony Waka Udezi, President, ISPOR Nigeria Chapter, Associate Professor & Assistant Dean, Department of Clinical Pharmacy, University of Benin, Benin City, Nigeria
Presentation
Abdalla Aly, Associate Scientist, Health Economics and Outcomes, Pharmerit International, Bethesda, MD, USA
Presentation
Paul La Cock, Consultant, inScisive, Cape Town, South Africa

 

F8 : INCORPORATING EQUITY INTO HTA: METHODS, TOOLS AND APPLICATIONS IN LATIN AMERICA

Presentation
Mike Paulden, Senior Research Associate, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
Presentation
Manuel Espinoza, Assistant Professor, Department of Public Health & Coordinator, Unit of Health Technology Assessment, Center for Clinical Investigation, Catholic University of Chile, Santiago, Chile
Presentation
Praveen Thokala, Research Fellow, University of Sheffield, Sheffield, UK

 

F9 : MANAGING COSTS AND IMPROVING QUALITY OF HEALTH CARE IN ASEAN

Presentation
Soraya Azmi, Managing Director, Azmi Burhani Consulting, Petaling Jaya, Malaysia
Presentation
Surachat Ngorsuraches, Associate Professor, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkla, Thailand
Presentation
Thuy Nguyen, Lecturer, Ho Chi Minh City University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam
Presentation
Bayu Teja Muliawan, Director, Pharmaceutical Service, Ministry of Health of the Republic of Indonesia, Jakarta, Indonesia
Presentation
Miny Lu, Director, Healthcare Economics, Policy and Reimbursement, Medtronic, Singapore, Singapore

 

F10 : THE ISSUES AND CHALLENGES FACING THE LIFE SCIENCE INDUSTRY TODAY

Presentation
Donald Yin, Associate Vice President, Merck & Co. Inc., Lebanon, NJ, USA
James F. Murray, Research Fellow, Global Health Outcomes - COE, Eli Lilly and Company, Carmel, IN, USA
John O’Donnell, Vice President, Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb Co., Princeton, NJ, USA

 

F11 : MANAGED ENTRY AGREEMENTS (MEA) IN EGYPT, LEBANON, SAUDI ARABIA, AND UNITED ARAB EMIRATES

Presentation
Abdulaziz H. Al-Saggabi, President, ISPOR Saudi Arabia Chapter and Director, Drug Policy & Economics Center, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia
Presentation
Mahmoud Elmahdawy, President, ISPOR Egypt Chapter, Chair-Elect , ISPOR Africa Network and Administrations Manager, Hospital Pharmacy, Ministry of Health, Cairo, Egypt
Presentation
Ola Ghaleb Al Ahdab, President, ISPOR United Arab Emirates Chapter and, Pharmaceutical Advisor & Project Manager, Registration and Drug Control Department, Ministry of Health, Abu Dhabi, United Arab Emirates
Presentation
Soumana Nasser, Clinical Associate Professor, Chair, Pharmacy Practice Department, School of Pharmacy, Lebanese American University, Byblos, Lebanon

 

F12 : FUNDING HEALTH TECHNOLOGY ASSESSMENT IN CENTRAL AND EASTERN EUROPEAN COUNTRIES: LOW PUBLIC BUDGET REFLECTS LOW PUBLIC PRIORITY?

Presentation
Vitaly Omelianovsky, President, ISPOR Russia HTA Chapter, Professor & Director, Center for Health Technology Assessment of the Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia
Presentation
Zoltán Kaló, Chair, ISPOR CEE Network Executive Committee, Professor of Health Economics, Department of Health Policy and Health Economics, Eötvös Loránd University (ELTE), Founder & CEO, Syreon Research Institute, Budapest, Hungary
Presentation
John Yfantopoulos, President, ISPOR Greece Chapter and Professor of Health Economics, School of Economics and Political Science, University of Athens, Athens, Greece
Vladimir Zah, PhD candidate and Health Economics Consultant & Founder, ZRx Outcomes Research Inc., Belgrade, Serbia and Montenegro

 

F13 : THE ROLE OF HTA IN THE QUEST TOWARDS UNIVERSAL COVERAGE IN MEXICO: A GOVERNMENT, ACADEMIC AND INDUSTRY PERSPECTIVE

Presentation
César Alberto Cruz Santiago, Advisor, Medical Director Area, PEMEX (Petróleos Mexicanos), Mexico City, Mexico
Gabriela Andrea Luna Ruíz, Professor, Economics Department, Universidad Iberoamericana, Ciudad de México, Mexico City, Mexico
Adolfo Hernández-Garduño, Access Planning Senior Manager, Access Department, Janssen Cilag Mexico, Mexico City, Mexico
Jocelyn Ramírez Gámez, Pharmacoeconomics Manager, Government Sales, Eli Lilly, Mexico City, Mexico

 

EDUCATIONAL SYMPOSIA

BIOSIMILARS ON THE RED CARPET: THE PHARMACOECONOMICS OF THEIR AMERICAN DEBUT

Presentation
Edward Li, Associate Professor, Department of Pharmacy Practice, University of New England College of Pharmacy, Portland, ME, USA
Tanya Bentley, Director, Health Economics and Outcomes Research, Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA
Bill Martin, Vice President, Pharmaceutical Strategies and Account Management, Accredo Health Group, Inc., Memphis, TN, USA

 

PRICING INNOVATION FOR NEW THERAPIES IN ADVANCED CANCERS: ADDRESSING AFFORDABILITY & THE PRACTICAL APPLICATION OF INNOVATIVE PRICING METHODS

Presentation
Colin Galbraith Wight, Chief Executive, GalbraithWight Ltd., Princeton, NJ, USA
Thomas Lönngren, Strategic Advisor, NDA Group, Stockholm, Sweden
Mark Boyden, Principal Consultant, Galbraithwight Limited, Polegate, UK
Mig Sleeper, Managing Director, Asera Consulting, Surrey, UK

 

DOES REAL WORLD EVIDENCE, IN THE GUISE OF PATIENT REGISTRIES, ADD ANY VALUE TO THE DECISION-MAKING PROCESS?

Presentation
Alex Exuzides, Director, Health Economics, ICON, plc., San Francisco, CA, USA
Manpreet Sidhu, Principal, US Health Economics and Epidemiology, ICON, Morristown, NJ, USA
Christopher M. Blanchette, Associate Dean, Research & Public Engagement, University of North Carolina at Charlotte, Charlotte, NC, USA
Gina Nicholson, Senior Health Economist, Health Economics & Epidemiology, ICON, plc., El Segundo, CA, USA
Lina Eliasson, Lead Outcomes Researcher, ICON PRO, Oxford, UK

 

EQ-5D-5L: DEVELOPMENT OF THE FIRST NATIONAL TARIFFS

Presentation
A. Simon Pickard, Professor, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA
Ben van Hout, Professor, HEDS, ScHARR, The University of Sheffield, Sheffield, UK
Jan van Busschbach, Professor, Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, The Netherlands
Kristina Secnik Boye, Director, Health Outcomes, Eli Lilly, Indianapolis, OH, USA

 

DEVELOPMENTS IN MEDICAL BIG DATA RESEARCH: UNITED STATES AND CHINA

Presentation
Mei Sheng Duh, Managing Principal, Analysis Group, Boston, MA, USA
Howard G. Birnbaum, Principal, Analysis Group, Inc., Boston, MA, USA
Eric Wu, Managing Principal, Analysis Group, Boston, MA, USA
Nabarun Dasgupta, Chief Data Scientist & Co-founder, Epidemico, Raleigh, NC, USA
Lisa Pinheiro, Vice President, Analysis Group, Montreal, QC, Canada

 

PODIUM AND POSTER PRESENTATIONS


For contributed research podium and poster abstracts and released slide or poster presentations for the ISPOR 20th Annual International Meeting, see: the ISPOR Scientific Presentations Database an electronic database of nearly 44,500 research papers presented at ISPOR International Conference, ISPOR European Conference, and ISPOR Asia-Pacific & Latin America Conferences from 1998 to date.

  • ISPOR Scientific Presentations Database
  • Under Meeting select ISPOR 20th Annual International Meeting – Philadelphia, PA, USA
  • Select Search for all research podium and poster abstracts and available slide or poster presentations from the meeting. Alternatively search by disease/disorder, topic or subtopic.
OPEN MEETINGS

ISPOR MEDICAL DEVICES & DIAGNOSTICS SPECIAL INTEREST GROUP OPEN MEETING (MEDICAL DEVICES)

Presentation
Anindiata Saha, Director, External Expertise and Partnerships, Center for Devices and Radiological Health, U.S. Food and Drug Administration
Martin Ho, Center for Devices and Radiological Health, U.S. Food and Drug Administration

 

EDUCATIONAL FORUM
STUDENT SHOWCASE
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.